Stock-Based Compensation |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-Based Compensation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-Based Compensation | 6) Stock-Based Compensation The Company held a special meeting of stockholders on April 10, 2025, at which the Company’s stockholders approved an amendment to the Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan (the “Incentive Plan”) to increase the aggregate number of shares of Common Stock available for the grant of awards under the Incentive Plan by 40,000,000, to a total of 40,110,400 shares of Common Stock. As of March 31, 2026, there were 40,110,400 shares authorized and 32,129,087 shares available for issuance under the Incentive Plan. The following is a summary of restricted stock awards and units for the three months ended March 31, 2026:
Stock-based compensation expense associated with restricted stock awards recognized for the three months ended March 31, 2026, was $120,319 and is recorded in general and administrative expenses in the consolidated statements of operations. As of March 31, 2026, unrecognized stock-based compensation expense is approximately $274,266 to be recognized over a term of 0.86 years. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||